share_log

8-K: HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

8-K: HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

8-K:HeartSciences提供最新業務並報告2025財年第一季度財務業績
美股SEC公告 ·  2024/09/12 16:20

Moomoo AI 已提取核心訊息

HeartSciences reported Q1 FY2025 results with $4.3M cash and $5.9M shareholder equity. The company secured additional $1.9M through non-dilutive financing and extended a $500,000 loan note to September 2025. Their MyoVista Insights AI-ECG cloud platform is on track for completion by end-2024, with FDA validation studies planned for their first cloud-based algorithm targeting low ejection fraction detection.The company plans FDA 510(k) submission for MyoVista wavECG device in Q1 2025, with hardware and software issues resolved and age-adjusted algorithm nearing completion. The Innovation Value Institute's analysis demonstrated MyoVista's potential to improve cardiovascular pathway efficiency, leading to the company's selection for demonstration at the UN General Assembly Digital Health Symposium.HeartSciences continues expanding its IP portfolio with new patents for deep learning-based ventricular dysfunction detection and MyoVista Wavelet Technology. The company is positioning itself in the projected $25B AI-ECG market through both cloud and device-based solutions, focusing on early heart disease detection.
HeartSciences reported Q1 FY2025 results with $4.3M cash and $5.9M shareholder equity. The company secured additional $1.9M through non-dilutive financing and extended a $500,000 loan note to September 2025. Their MyoVista Insights AI-ECG cloud platform is on track for completion by end-2024, with FDA validation studies planned for their first cloud-based algorithm targeting low ejection fraction detection.The company plans FDA 510(k) submission for MyoVista wavECG device in Q1 2025, with hardware and software issues resolved and age-adjusted algorithm nearing completion. The Innovation Value Institute's analysis demonstrated MyoVista's potential to improve cardiovascular pathway efficiency, leading to the company's selection for demonstration at the UN General Assembly Digital Health Symposium.HeartSciences continues expanding its IP portfolio with new patents for deep learning-based ventricular dysfunction detection and MyoVista Wavelet Technology. The company is positioning itself in the projected $25B AI-ECG market through both cloud and device-based solutions, focusing on early heart disease detection.
HeartSciences公佈了2025財年第一季度的財務報告,擁有430萬美元現金和590萬美元的股東權益。公司通過非稀釋性融資獲得了190萬美元,並將50萬美元的貸款票據延長至2025年9月。他們的MyoVista Insights人工智能-心電圖雲平台預計將在2024年底按期完成,並計劃對其第一個雲基礎算法進行FDA驗證研究,目標是檢測低射血分數。公司計劃在2025年第一季度提交MyoVista wavECG設備的FDA 510(k)申請,硬件和軟體問題已解決,並且年齡調整算法即將完成。創新價值研究所的分析顯示MyoVista在改善心血管路徑效率方面的潛力,從而使公司被選中在聯合國大會的...展開全部
HeartSciences公佈了2025財年第一季度的財務報告,擁有430萬美元現金和590萬美元的股東權益。公司通過非稀釋性融資獲得了190萬美元,並將50萬美元的貸款票據延長至2025年9月。他們的MyoVista Insights人工智能-心電圖雲平台預計將在2024年底按期完成,並計劃對其第一個雲基礎算法進行FDA驗證研究,目標是檢測低射血分數。公司計劃在2025年第一季度提交MyoVista wavECG設備的FDA 510(k)申請,硬件和軟體問題已解決,並且年齡調整算法即將完成。創新價值研究所的分析顯示MyoVista在改善心血管路徑效率方面的潛力,從而使公司被選中在聯合國大會的互聯網醫療研討會上進行展示。HeartSciences繼續擴展其知識產權組合,獲得了基於深度學習的心室功能障礙檢測和MyoVista小波技術的新專利。公司致力於通過雲和設備設計解決方案在預計250億美元的人工智能-心電圖市場中佔據一席之地,專注於早期心臟疾病檢測。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息